Methylphenidate Hydrochloride
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Methylphenidate Hydrochloride |
| DrugBank ID | DB00422 |
| Brand Names (EU) | Tuzulby |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 100.00% |
Approved Indication (EMA)
Tuzulby is indicated as part of a comprehensive treatment programme for attention-deficit / hyperactivity disorder (ADHD) in children and adolescents 6-17 years old when remedial measures alone prove insufficient. Treatment must be under the supervision of a specialist in childhood behavioural disorders. Diagnosis should be made according to Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria or the guidelines in International Classification of Diseases, Tenth
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | attention deficit-hyperactivity disorder | 100.00% | DL |
| 2 | faciodigitogenital syndrome | 100.00% | DL |
| 3 | attention deficit hyperactivity disorder, inattentive type | 100.00% | DL |
| 4 | chondromyxoid fibroma | 99.99% | DL |
| 5 | specific developmental disorder | 99.99% | DL |
| 6 | dysthymic disorder | 99.11% | DL |
| 7 | trichotillomania | 98.83% | DL |
| 8 | cerebellar ataxia | 98.39% | DL |
| 9 | autosomal dominant cerebellar ataxia | 98.38% | DL |
| 10 | spinocerebellar degeneration with slow eye movements | 97.57% | DL |
| 11 | benign paroxysmal torticollis of infancy | 97.51% | DL |
| 12 | insomnia (disease) | 97.51% | DL |
| 13 | transient tic disorder | 97.49% | DL |
| 14 | anxiety disorder | 97.30% | DL |
| 15 | narcolepsy | 97.05% | DL |
| 16 | Tourette syndrome | 96.76% | DL |
| 17 | hypersomnia (disease) | 96.10% | DL |
| 18 | agoraphobia | 96.01% | DL |
| 19 | circadian rhythm sleep disorder | 95.99% | DL |
| 20 | Balo concentric sclerosis | 95.76% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.